Search hospitals > Texas > Dallas
Medical City Dallas Hospital
Claim this profileDallas, Texas 75230
Global Leader in Cancer
Global Leader in Adult T-Cell Leukemia/Lymphoma
Conducts research for Lymphoma
Conducts research for Brain Tumor
Conducts research for Acute Lymphoblastic Leukemia
284 reported clinical trials
5 medical researchers
Summary
Medical City Dallas Hospital is a medical facility located in Dallas, Texas. This center is recognized for care of Cancer, Adult T-Cell Leukemia/Lymphoma, Lymphoma, Brain Tumor, Acute Lymphoblastic Leukemia and other specialties. Medical City Dallas Hospital is involved with conducting 284 clinical trials across 455 conditions. There are 5 research doctors associated with this hospital, such as Stanton C. Goldman, Bruce Bowers, M.D., Todd Dewey, M.D., and Vivian Dimas, MD.Area of expertise
1Cancer
Global LeaderStage IV
Stage I
Stage II
2Adult T-Cell Leukemia/Lymphoma
Global LeaderStage II
NTRK1 positive
NTRK positive
Top PIs
Stanton C. GoldmanMedical City Dallas Hospital8 years of reported clinical research
Expert in Cancer
Expert in Lymphoma
56 reported clinical trials
104 drugs studied
Bruce Bowers, M.D.Medical City Dallas6 years of reported clinical research
Studies Mitral Regurgitation
Studies Mitral Valve Regurgitation
3 reported clinical trials
6 drugs studied
Todd Dewey, M.D.Medical City Dallas6 years of reported clinical research
Studies Mitral Regurgitation
Studies Mitral Valve Disease
3 reported clinical trials
5 drugs studied
Vivian Dimas, MDMedical City Children's Hospital3 years of reported clinical research
Studies Cardiac Disease
Studies Congenital Heart Defects
3 reported clinical trials
4 drugs studied
Clinical Trials running at Medical City Dallas Hospital
Brain Tumor
Acute Lymphoblastic Leukemia
Testicular cancer
Adult T-Cell Leukemia/Lymphoma
Cancer
Testicular Carcinoma
Lymphoma
Rhabdomyosarcoma
Germ Cell Tumors
Ovarian Carcinoma
Selinexor + Radiation
for Brain Cancer
This trial tests the safety and effectiveness of combining selinexor with radiation therapy in children and young adults with aggressive brain tumors. Selinexor is a drug that blocks a protein to stop cancer cells from growing. The study aims to find the best dose and see if this combination can shrink tumors.
Recruiting1 award Phase 1 & 21 criteria
Lower Radiotherapy Dose
for Brain Tumors
This phase II trial studies how well lower dose radiotherapy after chemotherapy (Carboplatin \& Etoposide) works in treating children with central nervous system (CNS) germinomas. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Etoposide is in a class of medications known as podophyllotoxin derivatives. It blocks a certain enzyme needed for cell division and DNA repair and may kill cancer cells. Researchers want to see if lowering the dose of standard radiotherapy (RT) after chemotherapy can help get rid of CNS germinomas with fewer long-term side effects.
Recruiting1 award Phase 210 criteria
Chemotherapy + Radiation Therapy
for Brain Cancer
This phase II trial studies the best approach to combine chemotherapy and radiation therapy (RT) based on the patient's response to induction chemotherapy in patients with non-germinomatous germ cell tumors (NGGCT) that have not spread to other parts of the brain or body (localized). This study has 2 goals: 1) optimizing radiation for patients who respond well to induction chemotherapy to diminish spinal cord relapses, 2) utilizing higher dose chemotherapy followed by conventional RT in patients who did not respond to induction chemotherapy. Chemotherapy drugs, such as carboplatin, etoposide, ifosfamide, and thiotepa, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays or high-energy protons to kill tumor cells and shrink tumors. Studies have shown that patients with newly-diagnosed localized NGGCT, whose disease responds well to chemotherapy before receiving radiation therapy, are more likely to be free of the disease for a longer time than are patients for whom the chemotherapy does not efficiently eliminate or reduce the size of the tumor. The purpose of this study is to see how well the tumors respond to induction chemotherapy to decide what treatment to give next. Some patients will be given RT to the spine and a portion of the brain. Others will be given high dose chemotherapy and a stem cell transplant before RT to the whole brain and spine. Giving treatment based on the response to induction chemotherapy may lower the side effects of radiation in some patients and adjust the therapy to a more efficient one for other patients with localized NGGCT.
Recruiting1 award Phase 2
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Medical City Dallas Hospital?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.